Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,479 Financial Services 1,900 Healthcare 1,116 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 337 Consumer Defensive 248 Communication Services 213 Utilities 183 Energy 165 Real Estate 80

1,116 stocks · page 9 of 19

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

IGC Pharma, Inc.

Market implies +46.9%/yr vs model +2.0% · above model

Inhibikase Therapeutics, Inc.

Market implies +107.3%/yr vs model +2.0% · above model

Market implies +17.7%/yr vs model +3.0% · above model

ImageneBio, Inc.

Market implies +53.3%/yr vs model +2.0% · above model

IM Cannabis Corp.

Immunocore Holdings plc

Deeply undervalued

Discount 63% Return to IV: +167.8%

Market implies -19.3%/yr vs model +50.0% · below model

Insight Molecular Diagnostics Inc.

Market implies +51.7%/yr vs model +16.5% · above model

Immix Biopharma, Inc.

Market implies +103.6%/yr vs model +15.0% · above model

Market implies +11.3%/yr vs model +15.0% · below model

Immuneering Corp

Market implies +93.3%/yr vs model +15.0% · above model

Immunovant, Inc.

INTELLIGENT BIO SOLUTIONS INC.

Deeply overvalued

Premium +223% Return to IV: -69.0%

Market implies +9.1%/yr vs model +11.4% · in line

Inhibrx Biosciences, Inc.

Market implies +150.0%/yr vs model +2.0% · above model

Indaptus Therapeutics, Inc.

Indivior Pharmaceuticals, Inc.

Market implies -5.4%/yr vs model +15.0% · below model

InfuSystem Holdings, Inc

Premium +18% Return to IV: -15.4%

Owner yield 7.0% 10-yr IRR 16.2% · moderate

Market implies +8.6%/yr vs model +10.3% · in line

Deeply undervalued

Discount 45% Return to IV: +80.7%

Market implies -12.7%/yr vs model +2.0% · below model

MiNK Therapeutics, Inc.

InMed Pharmaceuticals Inc.

Deeply undervalued

Discount 89% Return to IV: +791.9%

Market implies -49.8%/yr vs model +26.9% · below model

Inmune Bio, Inc.

Market implies +123.8%/yr vs model +2.0% · above model

Deeply undervalued

Discount 30% Return to IV: +43.3%

Owner yield 13.4% 10-yr IRR 25.5% · moderate

Market implies +0.5%/yr vs model +7.6% · below model

InnovAge Holding Corp.

Deeply overvalued

Premium +414% Return to IV: -80.5%

Market implies +28.8%/yr vs model +8.3% · above model

INOVIO PHARMACEUTICALS, INC.

Market implies +101.8%/yr vs model +2.0% · above model

Deeply overvalued

Premium +410% Return to IV: -80.4%

Market implies +13.6%/yr vs model +33.9% · below model

Inspire Medical Systems, Inc.

Deeply undervalued

Model IV$180.13

Discount 59% Return to IV: +146.8%

Market implies -16.3%/yr vs model +40.6% · below model

INTENSITY THERAPEUTICS, INC.

Deeply overvalued

Premium +147% Return to IV: -59.4%

Owner yield 5.5% 10-yr IRR 11.3% · moderate

Market implies +17.1%/yr vs model +8.3% · above model

Deeply undervalued

Discount 68% Return to IV: +210.2%

Owner yield 10.0% 10-yr IRR 19.0% · moderate

Market implies -9.4%/yr vs model +6.5% · below model

IONIS PHARMACEUTICALS INC

Market implies +9.6%/yr vs model +3.9% · above model

IOVANCE BIOTHERAPEUTICS, INC.

Market implies -50.0%/yr vs model +15.0% · below model

Innate Pharma SA

Century Therapeutics, Inc.

Deeply overvalued

Premium +242% Return to IV: -70.8%

Market implies +22.7%/yr vs model +15.0% · above model

Opus Genetics, Inc.

Deeply overvalued

Premium +278% Return to IV: -73.5%

Market implies +16.1%/yr vs model +50.0% · below model

Deeply undervalued

Discount 83% Return to IV: +481.8%

Market implies -32.8%/yr vs model +7.6% · below model

Deeply overvalued

Premium +122% Return to IV: -54.9%

Owner yield 1.3% 10-yr IRR -2.2% · grower

Market implies +22.0%/yr vs model +16.3% · above model

Disc Medicine, Inc.

iRhythm Holdings, Inc.

Model IV$106.15

Premium +5% Return to IV: -4.7%

Market implies -4.6%/yr vs model +23.3% · below model

IRONWOOD PHARMACEUTICALS INC

Discount 15% Return to IV: +18.1%

Owner yield 20.7% 10-yr IRR 29.3% · steady

Market implies -2.4%/yr vs model +2.0% · below model

INTUITIVE SURGICAL INC

Deeply overvalued

Model IV$135.74

Premium +190% Return to IV: -65.5%

Owner yield 1.1% 10-yr IRR -5.1% · grower

Market implies +24.9%/yr vs model +13.7% · above model

Integer Holdings Corp

Deeply overvalued

Premium +90% Return to IV: -47.4%

Owner yield 2.0% 10-yr IRR -0.2% · moderate

Market implies +16.8%/yr vs model +10.7% · above model

iTonic Holdings Ltd

Market implies +56.3%/yr vs model +2.0% · above model

Discount 0% Return to IV: +0.1%

Owner yield 5.3% 10-yr IRR 9.0% · moderate

Market implies +5.2%/yr vs model +6.2% · in line

INVO Fertility, Inc.

Market implies -50.0%/yr vs model +50.0% · below model

Market implies +21.5%/yr vs model +15.0% · above model

Incannex Healthcare Inc.

Market implies +123.1%/yr vs model +15.0% · above model

Jaguar Health, Inc.

Market implies -50.0%/yr vs model +27.7% · below model

Janux Therapeutics, Inc.

Market implies +55.1%/yr vs model +28.8% · above model

Jazz Pharmaceuticals plc

Deeply undervalued

Model IV$483.86

Discount 49% Return to IV: +96.9%

Owner yield 8.3% 10-yr IRR 17.9% · moderate

Market implies -1.4%/yr vs model +8.9% · below model

Jade Biosciences, Inc.

JOHNSON & JOHNSON

Model IV$223.02

Premium +21% Return to IV: -17.4%

Owner yield 2.8% 10-yr IRR 1.4% · moderate

Market implies +8.5%/yr vs model +7.3% · in line

Jasper Therapeutics, Inc.